OrthoPediatrics Corp. Q3 2025 Earnings Release

OrthoPediatrics Corp. reported its financial results for the third quarter of 2025, with total revenue increasing by 12% year-over-year to $61.2 million. Domestic revenue grew by 14%, while international revenue increased by 6%. The company achieved a 56% increase in adjusted EBITDA, reaching $6.2 million. Despite these gains, the company reported a GAAP diluted loss per share of $(0.50), compared to $(0.34) in the same period last year. Key highlights include the completion of the first procedures with the VerteGlide™ Spinal Growth Guidance System and FDA approval for the 3P™ Pediatric Plating Platform™ Small-Mini System. The company also updated its full-year 2025 revenue guidance to a range of $233.5 million to $234.5 million, representing a 14% to 15% growth over 2024.